Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

IMPORTANCE: Microsatellite stable (MSS) metastatic colorectal cancer has been historically characterized as resistant to immunotherapy. Recent studies have demonstrated limited clinical activity of programmed cell death receptor 1/programmed death ligand 1 (PD-1/PD-L1) targeting in MSS metastatic co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chongkai, Sandhu, Jaideep, Ouyang, Ching, Ye, Jian, Lee, Peter P., Fakih, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353537/
https://www.ncbi.nlm.nih.gov/pubmed/34369992
http://dx.doi.org/10.1001/jamanetworkopen.2021.18416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353537/
https://www.ncbi.nlm.nih.gov/pubmed/34369992
http://dx.doi.org/10.1001/jamanetworkopen.2021.18416

Ejemplares similares